cancer

A pioneer in cancer immunology, Dr. Antoni Ribas has devoted his career to developing and refining new therapies for malignant melanoma.

The research opens up the possibility of using drugs that simulate viruses to overcome immunotherapy resistance in melanoma.

Spanning medicine, math and nanomaterials, support for campus scientific studies has grown almost 40% in five years.

The team will investigate the mechanisms of treatment resistance, laying the groundwork for new and improved combination therapies.

One of the most effective preventive measures is germline sequencing, which can detect gene mutations known to increase disease risk.

Research brief: UCLA researchers found that chemotherapy is often underutilized when treating adults with sarcoma, a rare type of cancer of the soft tissues or bone.

Research brief: A new combination treatment shows success in a mouse model of advanced head and neck carcinoma.

Research brief: A study shows that while both are factors, a higher proportion of physicians report patients' safety as a concern.

Research brief: A study shows that the proportion of vaccinated adolescents is higher in most states that require students to receive the vaccine.

The award from the National Cancer Institute will fund a series of collaborative research projects over five years at UCLA.

The immunotherapy drug combination is currently being reviewed for approval under a new FDA pilot program.

By repurposing drugs originally intended for other uses, scientists are pushing forward the fight against cancer.

“We hope our method could be used in the future to prepare treatments that can be performed at the patient’s bedside,” said UCLA’s Paul Weiss.

Research brief: The experiment represents one of a very few instances in which a drug reduced cognitive decline in animals after radiation treatment.

A Q&A with Dr. Eric Esrailian on the  Robert G. Kardashian Center for Esophageal Health and outreach efforts around COVID-19.

A UCLA study shows that radiation therapy can be cut from five weeks to five days.

The patch significantly prolonged survival and reduced the growth of tumors in mice.

Research brief: The drug is made up of compounds produced by plants, including curcumin. Curcumin has been tested to help fight multiple cancers because it is an antioxidant that reduces swelling and inflammation.

Research brief: When tested in mice with melanoma tumors that were unlikely to stimulate an immune response, the approach increased the number of anti-tumor immune cells.

The funds will help the Simms/Mann–UCLA Center for Integrative Oncology expand its reach to community clinics.

The drug combination should be a first line of treatment, UCLA researchers say.

A combination approach could be new strategy for people with advanced cancers.

Scientists from 22 institutions, including UCLA, call for early diagnosis, prevention and treatment to reduce the risk of chronic diseases.

Research brief: The new method, using robotics, will speed up how researchers test for therapies that block the metabolism of non-small-cell lung cancer tumors.

The finding could lead to better treatments for leukemia and other blood diseases.